Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
Patel P, Ford SL, Baker M, Meyer C, Garside L, D'Amico R, Van Solingen-Ristea R, Crauwels H, Polli JW, Seal C, Yagüe Muñoz I, Thiagarajah S, Birmingham E, Spreen WR, Baugh B, van Wyk J, Vannappagari V. Patel P, et al. Among authors: ford sl. HIV Med. 2023 May;24(5):568-579. doi: 10.1111/hiv.13439. Epub 2022 Nov 21. HIV Med. 2023. PMID: 36411596
Formulation and pharmacology of long-acting cabotegravir.
Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S. Trezza C, et al. Among authors: ford sl. Curr Opin HIV AIDS. 2015 Jul;10(4):239-45. doi: 10.1097/COH.0000000000000168. Curr Opin HIV AIDS. 2015. PMID: 26049948 Free PMC article. Review.
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.
Bowers GD, Culp A, Reese MJ, Tabolt G, Moss L, Piscitelli S, Huynh P, Wagner D, Ford SL, Gould EP, Pan R, Lou Y, Margolis DA, Spreen WR. Bowers GD, et al. Among authors: ford sl. Xenobiotica. 2016;46(2):147-62. doi: 10.3109/00498254.2015.1060372. Epub 2015 Jul 1. Xenobiotica. 2016. PMID: 26134155 Clinical Trial.
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA, Brinson CC, Smith GHR, de Vente J, Hagins DP, Eron JJ, Griffith SK, Clair MHS, Stevens MC, Williams PE, Ford SL, Stancil BS, Bomar MM, Hudson KJ, Smith KY, Spreen WR; LAI116482 Study Team. Margolis DA, et al. Among authors: ford sl. Lancet Infect Dis. 2015 Oct;15(10):1145-1155. doi: 10.1016/S1473-3099(15)00152-8. Epub 2015 Jul 19. Lancet Infect Dis. 2015. PMID: 26201299 Clinical Trial.
111 results